迈威生物拟赴港上市 骨健康创新药项目将落地重庆

Group 1 - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to meet funding needs and enhance internationalization [1] - The company is in discussions with intermediaries regarding the H-share issuance, with significant uncertainties regarding approval and implementation [1] - The company aims to leverage the national strategy for the western development to expand both domestic and international markets through a partnership with the Chongqing High-tech Zone Management Committee [1][4] Group 2 - The total planned investment for the bone health innovation drug project is 2 billion yuan, with the company investing no less than 1.6 billion yuan [2] - The project will be operated by the company's wholly-owned subsidiary, and the registered capital of this subsidiary will be increased from 20 million yuan to 1.008 billion yuan [2][3] - The investment will include contributions in the form of intangible assets, specifically the technology achievements of an already listed biological drug [2][3] Group 3 - The project will allow the subsidiary to become the marketing authorization holder for the drug, gaining rights for research, production, and commercialization [3] - The project aims to establish a national marketing center and conduct clinical research for expanding indications of the drug [3][4] - The local government will support the company's drug promotion and services, targeting over 1 million elderly individuals annually [4][5]